Presentations & Events

PHAR presented research spanning the spanning the areas of rare disease, oncology, neurology, and infectious disease. Three of their posters examined and reported on the use of genomic screening/testing to improve outcomes in multiple types of advanced cancers. PHAR’s researchers also contributed to three posters on the benefits of a novel antiviral treatment for COVID-19, on the development of algorithms to identify non-relapsing secondary progressive multiple sclerosis in electronic health data, and on healthcare resource utilization and costs related to the management of tuberous sclerosis complex, a rare genetic disorder.

All of these posters can be found on the PHAR publications page, and accompanying abstracts will be published in the June 2023 ISPOR supplement of Value in Health.

PHAR investigators, in partnership with Genentech, Inc., conducted an insurance claims analysis to examine how real-world treatment of chronic spontaneous urticaria (CSU) among commercially insured and Medicaid patients aligns with current global treatment guidelines. PHAR’s Sheila Reddy, PhD, MSc, RPh, Eunice Chang, PhD, and Marian Tarbox, MPP found that adherence to treatment-based guidelines for CSU was generally low in both populations of patients, and described treatment patterns at the annual meeting of the American Academy of Allergy, Asthma & Immunology. The poster can be viewed here, and the abstract was published in the February supplement issue of the Journal of Allergy and Clinical Immunology.

PHAR, in collaboration with Genentech, presented findings from further validation of their claims-based algorithm used to identify patients with neuromyelitis optica spectrum disorder (NMOSD), a disorder that can be difficult to distinguish from other demyelinating central nervous system (CNS) disorders in clinical practice.

Earlier this year, PHAR developed an algorithm to distinguish patients with NMOSD from patients with multiple sclerosis and other CNS inflammatory disorders, validating it in a proxy insurance claims database derived from billing and medication records from three neurology care centers. Interim results were presented at ACTRIMS Forum 2022. Since then, PHAR has further demonstrated the performance of the algorithm in a dataset of 101 patients from five neurology care clinics and has tested its face validity using 2016–2019 data from IBM® MarketScan® Commercial and Medicare Supplemental databases. Their poster was presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), and the abstract was published in the October supplement issue of Multiple Sclerosis Journal.

PHAR’s Sheila Reddy, PhD, MSc, RPh, Eunice Chang, PhD, and Marian Tarbox, MPP, in collaboration with Genentech, Inc., described treatment patterns, including alignment with guidelines, omalizumab and corticosteroid use, and specialist visits, for patients with chronic spontaneous urticaria in the real world in a retrospective study utilizing Merative™ MarketScan® commercial and Medicaid databases.

These findings were presented at AMCP Nexus; the poster can be viewed here, and the abstract was published in the October supplement issue of the Journal of Managed Care & Specialty Pharmacy.

PHAR investigators, in collaboration with Novartis Pharmaceuticals, presented practical recommendations on the prevention and management of adverse events from Piqray (alpelisib) in the treatment of advanced breast cancer at the ASCO (American Society of Clinical Oncology) Quality Care Symposium.

Earlier this year, PHAR’s Hannah Dalglish, MPH, Sarah Gibbs, MPH, and Michael Broder, MD, MSHS conducted two modified Delphi panels with 20 experts to gather practical, easy-to-implement guidance on the prevention and management of hyperglycemia and rash related to treatment with alpelisib. The Delphi panel methodology provided a systematic and validated approach to creating clinical consensus among the experts, including oncologists, dermatologists, endocrinologists, and patient advocates. The poster can be found on the PHAR publications page, and the abstract was published in the October supplement issue of the Journal of Clinical Oncology.

In addition to finding consensus, the Delphi approach also identified areas of disagreement. Future research may further refine these areas, in addition to testing whether recommendations affect patient outcomes.

At ENDO2022, Endocrine Society’s annual meeting, PHAR’s Ashis Kumar Das, MBBS, MPH, PhD, Cynthia Campos, MPH, and Michael S. Broder, MD, MSHS presented two posters on the ILLUSTRATE study, conducted in collaboration with Recordati Rare Diseases, Inc. ILLUSTRATE is a real-world retrospective chart review of osilodrostat usage in U.S. patients with endogenous Cushing’s syndrome. The first poster describes osilodrostat dosing, titration, and persistence for patients with endogenous Cushing’s disease. The second describes osilodrostat use in a small sample of patients with non-pituitary Cushing’s syndrome. Until now, no information was available describing use of osilodrostat in non-pituitary CS as such use is not yet FDA-approved. The posters can be viewed here, and the abstracts will be published in a supplemental issue of the Journal of the Endocrine Society.